• Ritedose Corporation names Carolyn Berg as VP of Strategic Growth

  US-based CDMO Ritedose Corporation, which manufactures its own inhalation products in addition to offering contract manufacturing services, has announced the appointment of experienced inhalation business executive Carolyn Berg as VP of Strategic Growth. Berg was most recently… [Read more . . .]

• FDA approves Aurobindo’s generic beclomethasone MDI

  According to Aurobindo Pharma, the FDA has issued a final approval of the company’s ANDA for 40 mcg and 80 mcg dose versions of a generic equivalent of Teva’s QVAR beclomethasone HFA MDI for the… [Read more . . .]

• Zeteo Biomedical announces the launch of its new AriesMR active DPI

  Drug delivery specialist Zeteo Biomedical has announced the availability of its first device for delivery to the lung, the AriesMR DPI, which the company describes as “a reloadable active dry powder inhaler designed for controlled… [Read more . . .]

• Agomab reports results from Phase 1 study of AGMB-447 inhaled ALK5 inhibitor

  Agomab Therapeutics has announced that the final part of a Phase 1 study of its AGMB-447 inhaled ALK5 inhibitor, which enrolled patients with idiopathic pulmonary fibrosis, demonstrated “a generally favorable safety and tolerability profile” in… [Read more . . .]

• Cystic Fibrosis Foundation to make strategic investment of up to $7.3 million in Ride Therapeutics to support development of inhaled genetic therapies for CF

  The Cystic Fibrosis Foundation has agreed to invest up to $7.3 million in Ride Therapeutics to support identification of potential delivery vehicles for inhaled genetic therapies for CF. According to the CFF, Ride plans to test millions… [Read more . . .]

• FDA clears IND for Nasus’s NS002 epinephrine nasal powder for the treatment of anaphylaxis

• Aptar and MGH partner on development of platform to aid development of nose-to-brain therapies

• Hikma announces regulatory submissions for its epinephrine nasal spray in the US, UK, Europe, and Canada

• Ethris gets €30 million financing through the European Investment Bank and the EC’s Health Emergency Preparedness and Response Authority for development of inhaled and nasal mRNA vaccines

• Pulmovant says Phase 2 PHocus trial of its mosliciguat DPI met its primary endpoint, Phase 3 PHrontier trial has been initiated

More news . . .